The HHS and FDA are encouraging stakeholders to submit their ideas for deregulatory actions in the next 60 days.

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

Pharmaceutical tariffs could increase drug prices and drug shortages, negatively impacting the health care system, experts ...

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The guidelines now state that vorasidenib may be an option for certain patients.